Kindeva will showcase its major investments in manufacturing infrastructure, including the recent inauguration of its Bridgeton, US facility, which significantly expands the company's sterile injectable capabilities. The booth will also highlight the newly expanded UK headquarters in Loughborough, which is leading the industry's transition to low global warming potential (GWP) next-generation propellants (NGPs) for pressurized metered-dose inhalers (pMDIs).
Visit with key members of Kindeva’s leadership team, including CEO Milton Boyer, COO David Stevens, Senior Vice President of the Metered-Dose Inhaler (MDI) business unit Craig Somerville and Senior Vice President of Injectables, Tommy Schornak, who will be at the booth to discuss strategic partnerships and the future of drug delivery.
A highlight of the event will be a presentation by Chad Hafer, Director of Manufacturing & Aseptic Technical Operations at Kindeva, titled "A Bridge to the Future of Aseptic Manufacturing: A Pharma 4.0 case study," on October 29th at 14:00 in the Manufacturing 5.0 Theatre.
Kindeva’s commitment to shaping the future of medicine extends to its leadership in sustainability, which has been honoured with a nomination in the prestigious CPHI Pharma Awards.
Driven by its purpose to manufacture more tomorrows, Kindeva invites CPHI attendees to visit their booth, enjoy a coffee at their on-stand café, and discover how its end-to-end capabilities can advance the next generation of drug-device combination products.